Researcher Emphasizes Opportunities for Drug Target Discovery Based on Cancer Heterogeneity at AACR | GenomeWeb

By Andrea Anderson

CHICAGO (GenomeWeb News) – There may be ways to exploit the extensive heterogeneity being uncovered through genome sequencing and other studies of cancer as a means for coming up with new treatment targets and identifying promising drug candidates, according to one presenter at this year's American Association for Cancer Research annual meeting.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nature this week: genome-wide transcriptome analysis of brain samples from people with autism spectrum disorder, flounder genome, and more.

Researchers used T-cell transfer therapy to target mutation KRAS, according to the New York Times.

The US Senate has passed the 21st Century Cures Act, which would provide a funding boost at NIH while overhauling FDA policies.

Bloomberg reports that President-elect Donald Trump is considering Jim O'Neill for Food and Drug Administration commissioner.